Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
30/09/2026 12:01
BRIEF-Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection Sept 30 (Reuters) - Kailera Therapeutics Inc KLRA.O:
KAILERA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN KAINETIC GLOBAL PHASE 3 CLINICAL PROGRAM OF GLP-1/GIP RECEPTOR DUAL AGONIST RIBUPATIDE INJECTION
KAILERA THERAPEUTICS - TOPLINE DATA FROM KAINETIC PHASE 3 TRIALS EXPECTED IN MID-2028
Source text: ID:nGNX566yzZ
Further company coverage: KLRA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Kailera Therapeutics
See all newsChina biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection